--- title: "Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces Board Appointments" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/266617933.md" description: "Zhejiang Hisoar Pharmaceutical Co., Ltd. held its 1st Extraordinary General Meeting of 2025 on 18 November 2025, approved the appointment of Chen Guangshun, non-independent director, Chen Fangqi, non-independent director." datetime: "2025-11-19T21:11:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/266617933.md) - [en](https://longbridge.com/en/news/266617933.md) - [zh-HK](https://longbridge.com/zh-HK/news/266617933.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/266617933.md) | [English](https://longbridge.com/en/news/266617933.md) # Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces Board Appointments Zhejiang Hisoar Pharmaceutical Co., Ltd. held its 1st Extraordinary General Meeting of 2025 on 18 November 2025, approved the appointment of Chen Guangshun, non-independent director, Chen Fangqi, non-independent director. ### 相關股票 - [HISOAR (002099.CN)](https://longbridge.com/zh-HK/quote/002099.CN.md) ## 相關資訊與研究 - [Stitt signs executive order declaring a state of emergency for NE OK](https://longbridge.com/zh-HK/news/278230168.md) - [Mesa Laboratories Names New CEO for Next Phase](https://longbridge.com/zh-HK/news/278450802.md) - [Santhera Pharma Appoints Marc Clausse As Chief Commercial Officer](https://longbridge.com/zh-HK/news/278499117.md) - [](https://longbridge.com/zh-HK/news/278405131.md) - [BYD reportedly explores F1 entry to boost global brand appeal](https://longbridge.com/zh-HK/news/278576491.md)